GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Cyclically Adjusted PS Ratio

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Cyclically Adjusted PS Ratio : 8.37 (As of May. 17, 2024)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-17), BioCryst Pharmaceuticals's current share price is $6.28. BioCryst Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.75. BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 8.37.

The historical rank and industry rank for BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

BCRX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.66   Med: 9.2   Max: 45.08
Current: 8.63

During the past years, BioCryst Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 45.08. The lowest was 1.66. And the median was 9.20.

BCRX's Cyclically Adjusted PS Ratio is ranked worse than
61.99% of 513 companies
in the Biotechnology industry
Industry Median: 5.51 vs BCRX: 8.63

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BioCryst Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.450. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCryst Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Cyclically Adjusted PS Ratio Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.50 19.56 31.26 20.93 8.56

BioCryst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.25 11.12 10.43 8.56 6.78

Competitive Comparison of BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



BioCryst Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=6.28/0.75
=8.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCryst Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, BioCryst Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.45/131.7762*131.7762
=0.450

Current CPI (Mar. 2024) = 131.7762.

BioCryst Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.023 100.560 0.030
201409 0.045 100.428 0.059
201412 0.076 99.070 0.101
201503 0.094 99.621 0.124
201506 0.337 100.684 0.441
201509 0.150 100.392 0.197
201512 0.063 99.792 0.083
201603 0.065 100.470 0.085
201606 0.065 101.688 0.084
201609 0.105 101.861 0.136
201612 0.122 101.863 0.158
201703 0.126 102.862 0.161
201706 0.039 103.349 0.050
201709 0.105 104.136 0.133
201712 0.039 104.011 0.049
201803 0.040 105.290 0.050
201806 0.126 106.317 0.156
201809 0.014 106.507 0.017
201812 0.025 105.998 0.031
201903 0.053 107.251 0.065
201906 0.013 108.070 0.016
201909 0.016 108.329 0.019
201912 0.302 108.420 0.367
202003 0.031 108.902 0.038
202006 0.018 108.767 0.022
202009 0.035 109.815 0.042
202012 0.023 109.897 0.028
202103 0.107 111.754 0.126
202106 0.280 114.631 0.322
202109 0.229 115.734 0.261
202112 0.259 117.630 0.290
202203 0.270 121.301 0.293
202206 0.353 125.017 0.372
202209 0.407 125.227 0.428
202212 0.426 125.222 0.448
202303 0.365 127.348 0.378
202306 0.436 128.729 0.446
202309 0.457 129.860 0.464
202312 0.464 129.419 0.472
202403 0.450 131.776 0.450

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCryst Pharmaceuticals  (NAS:BCRX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioCryst Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie director C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan officer: SR VP - CMO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Headlines

From GuruFocus